Insm - dá-lhe gás?
Mais insider buying!
é a quarta pessoa da empresa que compra acções nos ultimos dias! Provavelmente noticias explosivas estão a chegar! (está a ser uma festa)
Se for anunciado uma parceria com uma outra empresa da area este stock vai duplicar, triplicar de valor rapidamente. E ainda falta os resultados dos testes de um novo medicamento que esta a ser testado em Itália!!!
http://xml.10kwizard.com/filing_raw.php ... ge=5018678
Fica o aviso!
Bons trades
é a quarta pessoa da empresa que compra acções nos ultimos dias! Provavelmente noticias explosivas estão a chegar! (está a ser uma festa)
Se for anunciado uma parceria com uma outra empresa da area este stock vai duplicar, triplicar de valor rapidamente. E ainda falta os resultados dos testes de um novo medicamento que esta a ser testado em Itália!!!
http://xml.10kwizard.com/filing_raw.php ... ge=5018678
Fica o aviso!
Bons trades
- Mensagens: 171
- Registado: 30/6/2006 17:30
lei aprovada
ver link:
http://help.senate.gov/Maj_press/2007_06_27_c.pdf
Mais Insider Buying (dia 27 de Junho de 2007):
http://www.shareholder.com/Common/Edgar ... /07-00.pdf
http://help.senate.gov/Maj_press/2007_06_27_c.pdf
Mais Insider Buying (dia 27 de Junho de 2007):
http://www.shareholder.com/Common/Edgar ... /07-00.pdf
- Mensagens: 171
- Registado: 30/6/2006 17:30
Se estivesse a descer antes da decisão acho que era mais confortável tal como está a acontecer com a NUVO e AVNR agora a subir e com pouco volume deixa-me apreensivo ainda mais a subir no mesmo dia da decisão ...., mas nunca se sabe até pode ser que sobe ou até pode nem mexer 
- Mensagens: 80
- Registado: 26/10/2006 14:26
Insider Buying - Informação
Steve Glover, INSM President Follow-on Biologics
BUY 6/25/07 80,000 shares
Geoffrey Allan, INSM President, CEO and Chairman
BUY 6/21/07 165,000 shares
estou dentro! (cheio delas!)
(vamos lá ver o que se vai passar)
BUY 6/25/07 80,000 shares
Geoffrey Allan, INSM President, CEO and Chairman
BUY 6/21/07 165,000 shares
estou dentro! (cheio delas!)
(vamos lá ver o que se vai passar)
- Mensagens: 171
- Registado: 30/6/2006 17:30
Boas XPTO...
... estou desde os 0,70 e ontem estive para arrecadar as mais valias.
Achas que tem hipoteses de se safarem ?
Vou colocar stop para evitar surpresas.
BN
Achas que tem hipoteses de se safarem ?
Vou colocar stop para evitar surpresas.
BN
-
- Mensagens: 411
- Registado: 5/11/2002 10:37
- Localização: Paço de Arcos
Vamos ver , mas olhando financeiramente , eu desaprovo , com os proximos dois trimestres a cavarem mais prejuizos baseando-me nas previsoes.
Para alem do mais, a cotaçao revela uma descrença total , com sucessivos minimos.
Mas se for aprovado isso pode mudar , nao sei até que ponto , pode ser uma reviravolta.
No curto prazo póderá realmente elevar a cotaçao mas é necessario alterarem -se as perpectivas de medio ,longo prazo para que o possivel movimento nao acabe como começa.
Para alem do mais, a cotaçao revela uma descrença total , com sucessivos minimos.
Mas se for aprovado isso pode mudar , nao sei até que ponto , pode ser uma reviravolta.
No curto prazo póderá realmente elevar a cotaçao mas é necessario alterarem -se as perpectivas de medio ,longo prazo para que o possivel movimento nao acabe como começa.
-
- Mensagens: 833
- Registado: 19/10/2006 9:36
- Localização: 10
mais informação
Drug makers consider biological market
By Gregory Lopes
THE WASHINGTON TIMES
June 19, 2007
Manufacturers of generic drugs seem finally to have a golden opportunity to enter the huge biological-drug market as patents expire on more than $10 billion of brand-name pharmaceuticals.
However, they have two major hurdles to overcome: Congress must create an approval process for generic versions of the complicated and expensive drugs; and Congress may require price-prohibitive clinical trials if it approves generics.
Unlike chemically derived medications, biologics are made from living cell tissue and are used to treat rare disorders, making them far more expensive than conventional pharmaceuticals and more difficult to replicate. Avastin, a colorectal cancer biologic made by Genentech, can cost patients $5,500 a month.
An approval process does not exist, based on the premise that the drugs are too complicated to duplicate and thus ensure their safety.
Sen. Edward M. Kennedy, Massachusetts Democrat, has scheduled a vote for June 27 in the Senate Health, Education, Labor and Pensions Committee on a bill that would require the Food and Drug Administration to create an approval process for generic biologics.
The legislation, sponsored by Sens. Charles E. Schumer and Hillary Rodham Clinton, both New York Democrats, opens an approval process that does not require manufacturers to conduct lengthy and costly clinical trials on generic biologics. However, Mr. Kennedy and local biotech leaders favor such trials, which are required in Europe.
Barr Pharmaceuticals and Teva Pharmaceuticals, two of the leading generic-drug manufacturers in the country, have been sizing up the biological market for years and say they have the ability to create generic versions of biologics and sell them at cheaper prices. Each company has a generic version of a human growth hormone or insulin product in its pipeline, just waiting for the door to open as it did in Europe several years ago.
"I believe a federal approval process for biosimilar drugs is long overdue and will happen soon," said Bruce Downey, chief executive officer of Barr Pharmaceuticals. "It will not only save consumers billions of dollars a year but will allow more patients access to these important medications."
Mr. Downey is leading a coalition of drug companies, businesses and advocacy groups that include AARP, Ford Motor Co. and General Motors Corp. to lobby Congress to open the biotech industry to generic competition.
Biological drugs appeared 20 years ago on the U.S. market but did not immediately make a significant impact. In fact, the biological-drug market barely existed in 2004. But over the past several years, the drugs have taken off, with sales expected to reach $90 billion by 2009.
Mr. Downey said generic biological drugs probably would be priced similarly to generic drugs on the market, which typically cost one-third the price of the brand-name drug. Pharmacy benefits manager Express Scripts Inc. estimates that generic biotech drugs could save Americans $71 billion in a decade.
The biological-drug industry is weighing in on the legislation, pushing strongly for clinical trials that could hold up a biogeneric drug for several years.
By Gregory Lopes
THE WASHINGTON TIMES
June 19, 2007
Manufacturers of generic drugs seem finally to have a golden opportunity to enter the huge biological-drug market as patents expire on more than $10 billion of brand-name pharmaceuticals.
However, they have two major hurdles to overcome: Congress must create an approval process for generic versions of the complicated and expensive drugs; and Congress may require price-prohibitive clinical trials if it approves generics.
Unlike chemically derived medications, biologics are made from living cell tissue and are used to treat rare disorders, making them far more expensive than conventional pharmaceuticals and more difficult to replicate. Avastin, a colorectal cancer biologic made by Genentech, can cost patients $5,500 a month.
An approval process does not exist, based on the premise that the drugs are too complicated to duplicate and thus ensure their safety.
Sen. Edward M. Kennedy, Massachusetts Democrat, has scheduled a vote for June 27 in the Senate Health, Education, Labor and Pensions Committee on a bill that would require the Food and Drug Administration to create an approval process for generic biologics.
The legislation, sponsored by Sens. Charles E. Schumer and Hillary Rodham Clinton, both New York Democrats, opens an approval process that does not require manufacturers to conduct lengthy and costly clinical trials on generic biologics. However, Mr. Kennedy and local biotech leaders favor such trials, which are required in Europe.
Barr Pharmaceuticals and Teva Pharmaceuticals, two of the leading generic-drug manufacturers in the country, have been sizing up the biological market for years and say they have the ability to create generic versions of biologics and sell them at cheaper prices. Each company has a generic version of a human growth hormone or insulin product in its pipeline, just waiting for the door to open as it did in Europe several years ago.
"I believe a federal approval process for biosimilar drugs is long overdue and will happen soon," said Bruce Downey, chief executive officer of Barr Pharmaceuticals. "It will not only save consumers billions of dollars a year but will allow more patients access to these important medications."
Mr. Downey is leading a coalition of drug companies, businesses and advocacy groups that include AARP, Ford Motor Co. and General Motors Corp. to lobby Congress to open the biotech industry to generic competition.
Biological drugs appeared 20 years ago on the U.S. market but did not immediately make a significant impact. In fact, the biological-drug market barely existed in 2004. But over the past several years, the drugs have taken off, with sales expected to reach $90 billion by 2009.
Mr. Downey said generic biological drugs probably would be priced similarly to generic drugs on the market, which typically cost one-third the price of the brand-name drug. Pharmacy benefits manager Express Scripts Inc. estimates that generic biotech drugs could save Americans $71 billion in a decade.
The biological-drug industry is weighing in on the legislation, pushing strongly for clinical trials that could hold up a biogeneric drug for several years.
- Mensagens: 171
- Registado: 30/6/2006 17:30
The bill that could rock biotech
The bill that could rock biotech
Measure to create generic biotech drugs could hit Amgen, Genentech, but the bill's chances are uncertain.
By Aaron Smith, CNNMoney.com staff writer
April 30 2007: 5:24 PM EDT
NEW YORK (CNNMoney.com) -- Lawmakers are pushing forward with legislation that could help create generic competition for Big Biotech, drastically lowering the costs of expensive biotech drugs and changing the landscape in the pharmaceutical industry forever.
The Senate is expected to vote Wednesday on a bill that would extend the 15-year-old process of requiring drug companies to pay fees to the Food and Drug Administration to help fund the drug review process. Advocates say the law has helped streamline the review process so that it takes months instead of years to get lifesaving drugs approved for the market.
More drug news
Bristol taps CEO; profit slides
FDA experts support Pfizer's AIDS drug
Amgen earnings meet forecast
On the same day the Senate is voting, members of the House Energy and Commerce Committee are holding a hearing on a bill that would create a way for the FDA to review generic biotech drugs. Right now, there's nothing on generic biotech drugs in the Senate bill, and there's no guarantee that the bill will be modified.
Rep. Henry Waxman of California introduced a "biogenerics" bill in February along with Reps. Jo Ann Emerson of Missouri and Frank Pallone of New Jersey, as well Senators Hillary Clinton and Charles Schumer from New York.
The biogenerics bill would create a system for the FDA to review generic versions of biotech drugs, a $40 billion business in the United States last year, according to IMS Health, a drug industry research firm.
The bill has not yet been voted on in the House. Some believe that the best way to get the bill passed is for it to be folded into the FDA "reauthorization" bill, which has a much better chance of passing.
There is no biogenerics industry in America right now, so biotechs such as Amgen (up $0.88 to $64.14, Charts, Fortune 500) and Genentech (down $1.33 to $79.99, Charts) don't have to compete with generic companies like Teva Pharmaceuticals (Charts), Mylan Laboratories (Charts) or Barr Laboratories (Charts), which make low-cost versions of name-brand drugs after their patents expire.
Some of these biotech drugs costs tens of thousands of dollars a year. Genzyme (up $0.21 to $65.31, Charts) has drugs for rare diseases that can cost up to $200,000 annually. If a biogenerics bill gets through Congress, it could put serious pressure on these prices once the patents run out.
Andrea Hofelich, spokeswoman for the Generic Pharmaceutical Association (GPA), said making the biogenerics bill part of the broader legislation is the "best but not the only chance" of getting the bill passed in current congressional session.
Kathleen Jaeger, chief executive of the group, said she is "very optimistic" that a biogeneric bill will pass this year. "We do not believe that Congress can ignore the demand for biogenerics in this session," she said.
Where does Amgen stand in the Fortune 500?
But a system for biogenerics is not included in the reauthorization bill, and the deadline is fast approaching. Casey Alexander, analyst for Gilford Securities Inc., said it would be a "shame" if the bill doesn't pass because it "opens a tremendous world of opportunity" in providing low-cost drugs to patients.
Amgen, the world's leading biotech in terms of sales, is the company most likely to feel the impact of biogenerics if the bill goes through.
Amgen's blockbuster drugs Epogen and Neupogen, which are used to treat serious side effects from chemotherapy, could both get pressured by generic competition. These drugs are big earners for Amgen. Epogen, a treatment for chemo-induced anemia, totaled $2.5 billion in 2006 sales. Sales for the anti-infective Neupogen (combined with the drug Neulasta) totaled $1 billion in 2006.
Drugs are typically covered by numerous patents with different expiration dates, and the legal status of the drugs is often battled out in court by name-brand and generic drugmakers.
The patent on Epogen expired in Europe in 2004. According to the GPA, the earliest U.S. patent on the anemia drug expires in 2012. The earliest patents on Neupogen expired in the U.S. in 2006, said the GPA. But that's not how Amgen sees it. Amgen spokeswoman Kelly Davenport said that Neupogen's earliest U.S. patent doesn't expire until 2013.
Biotech drugs are created through living cell cultures, while pharmaceuticals are based on molecular compounds. Alexander of Gilford Securities said the leaders in the generic drug industry - Teva and Mylan - would be the most likely to benefit from the creation of a biogeneric business in the United States because they have the resources to make cheaper versions of the biotech medicines.
But the bill's chances are uncertain at best. Alexander is pessimistic it can pass in the Senate, while a vice president at generic drugmaker Barr Laboratories says the chances are "better than 50-50."
Barr is developing a biogeneric form of Epogen through its Pliva subsidiary in Croatia, said Jake Hansen, VP and U.S. government liaison for Barr. But the future of biogeneric Epogen is unclear, even though a regulatory system for approving it already exists in Europe.
"From a scientific point of view, we know it can be done, but we haven't made the decision on the economics," said Hansen. "We don't know if we're going ahead with Epogen even in Europe. The process in Europe, even though they allow biogenerics, is very cumbersome."
Measure to create generic biotech drugs could hit Amgen, Genentech, but the bill's chances are uncertain.
By Aaron Smith, CNNMoney.com staff writer
April 30 2007: 5:24 PM EDT
NEW YORK (CNNMoney.com) -- Lawmakers are pushing forward with legislation that could help create generic competition for Big Biotech, drastically lowering the costs of expensive biotech drugs and changing the landscape in the pharmaceutical industry forever.
The Senate is expected to vote Wednesday on a bill that would extend the 15-year-old process of requiring drug companies to pay fees to the Food and Drug Administration to help fund the drug review process. Advocates say the law has helped streamline the review process so that it takes months instead of years to get lifesaving drugs approved for the market.
More drug news
Bristol taps CEO; profit slides
FDA experts support Pfizer's AIDS drug
Amgen earnings meet forecast
On the same day the Senate is voting, members of the House Energy and Commerce Committee are holding a hearing on a bill that would create a way for the FDA to review generic biotech drugs. Right now, there's nothing on generic biotech drugs in the Senate bill, and there's no guarantee that the bill will be modified.
Rep. Henry Waxman of California introduced a "biogenerics" bill in February along with Reps. Jo Ann Emerson of Missouri and Frank Pallone of New Jersey, as well Senators Hillary Clinton and Charles Schumer from New York.
The biogenerics bill would create a system for the FDA to review generic versions of biotech drugs, a $40 billion business in the United States last year, according to IMS Health, a drug industry research firm.
The bill has not yet been voted on in the House. Some believe that the best way to get the bill passed is for it to be folded into the FDA "reauthorization" bill, which has a much better chance of passing.
There is no biogenerics industry in America right now, so biotechs such as Amgen (up $0.88 to $64.14, Charts, Fortune 500) and Genentech (down $1.33 to $79.99, Charts) don't have to compete with generic companies like Teva Pharmaceuticals (Charts), Mylan Laboratories (Charts) or Barr Laboratories (Charts), which make low-cost versions of name-brand drugs after their patents expire.
Some of these biotech drugs costs tens of thousands of dollars a year. Genzyme (up $0.21 to $65.31, Charts) has drugs for rare diseases that can cost up to $200,000 annually. If a biogenerics bill gets through Congress, it could put serious pressure on these prices once the patents run out.
Andrea Hofelich, spokeswoman for the Generic Pharmaceutical Association (GPA), said making the biogenerics bill part of the broader legislation is the "best but not the only chance" of getting the bill passed in current congressional session.
Kathleen Jaeger, chief executive of the group, said she is "very optimistic" that a biogeneric bill will pass this year. "We do not believe that Congress can ignore the demand for biogenerics in this session," she said.
Where does Amgen stand in the Fortune 500?
But a system for biogenerics is not included in the reauthorization bill, and the deadline is fast approaching. Casey Alexander, analyst for Gilford Securities Inc., said it would be a "shame" if the bill doesn't pass because it "opens a tremendous world of opportunity" in providing low-cost drugs to patients.
Amgen, the world's leading biotech in terms of sales, is the company most likely to feel the impact of biogenerics if the bill goes through.
Amgen's blockbuster drugs Epogen and Neupogen, which are used to treat serious side effects from chemotherapy, could both get pressured by generic competition. These drugs are big earners for Amgen. Epogen, a treatment for chemo-induced anemia, totaled $2.5 billion in 2006 sales. Sales for the anti-infective Neupogen (combined with the drug Neulasta) totaled $1 billion in 2006.
Drugs are typically covered by numerous patents with different expiration dates, and the legal status of the drugs is often battled out in court by name-brand and generic drugmakers.
The patent on Epogen expired in Europe in 2004. According to the GPA, the earliest U.S. patent on the anemia drug expires in 2012. The earliest patents on Neupogen expired in the U.S. in 2006, said the GPA. But that's not how Amgen sees it. Amgen spokeswoman Kelly Davenport said that Neupogen's earliest U.S. patent doesn't expire until 2013.
Biotech drugs are created through living cell cultures, while pharmaceuticals are based on molecular compounds. Alexander of Gilford Securities said the leaders in the generic drug industry - Teva and Mylan - would be the most likely to benefit from the creation of a biogeneric business in the United States because they have the resources to make cheaper versions of the biotech medicines.
But the bill's chances are uncertain at best. Alexander is pessimistic it can pass in the Senate, while a vice president at generic drugmaker Barr Laboratories says the chances are "better than 50-50."
Barr is developing a biogeneric form of Epogen through its Pliva subsidiary in Croatia, said Jake Hansen, VP and U.S. government liaison for Barr. But the future of biogeneric Epogen is unclear, even though a regulatory system for approving it already exists in Europe.
"From a scientific point of view, we know it can be done, but we haven't made the decision on the economics," said Hansen. "We don't know if we're going ahead with Epogen even in Europe. The process in Europe, even though they allow biogenerics, is very cumbersome."
- Mensagens: 171
- Registado: 30/6/2006 17:30
Insm - dá-lhe gás?
Provavelmente amanhã, o senado americano vai aprovar uma lei sobre os biogenéricos que pode ser um catalisador decisivo para uma subida abrupta desta acção.
Além disso, é de esperar para breve mais notícias sobre os ensaios que esta empresa de biotecnologia está a desenvolver.
Adiccionem esta acção à vossa Watch List.
Bons trades,
Um abraço
Link:
http://finance.yahoo.com/q/bc?s=INSM&t=1d
Além disso, é de esperar para breve mais notícias sobre os ensaios que esta empresa de biotecnologia está a desenvolver.
Adiccionem esta acção à vossa Watch List.
Bons trades,
Um abraço
Link:
http://finance.yahoo.com/q/bc?s=INSM&t=1d
- Mensagens: 171
- Registado: 30/6/2006 17:30
Quem está ligado:
Utilizadores a ver este Fórum: cali010201, Google [Bot], macau5m, nbms2012, OCTAMA, PAULOJOAO, peterteam2, Shimazaki_2 e 176 visitantes